Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

Share Price is delayed by 15 minutes
Get Live Data
652.00    12.00 (1.88%)
Bid:
644.00
Ask:
660.00
Spread: 16.00 (2.484%)
Market Cap: £219.22m
AVG Live PriceLast checked at - London Stock Exchange

Intraday Avingtrans Share Chart

Holding(s) in Company

6 Feb 2007 17:20

Avingtrans PLC06 February 2007 TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached (ii): Avingtrans PLC 2. Reason for the notification (please state Yes/No): ( ) An acquisition or disposal of voting rights: ( ) An acquisition or disposal of financial instruments which may result in theacquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : x 3. Full name of person(s) subject to the notification obligation (iii): JPMorgan Chase & Co 4. Full name of shareholder(s) (if different from 3.) (iv): JPMorgan Asset Management (UK) Limited 5. Date of the transaction (and date on which the threshold is crossed orreached if different) (v): N/A 6. Date on which issuer notified: 06 February 2007 7. Threshold(s) that is/are crossed or reached: 5% 8. Notified details: - A: Voting rights attached to shares Class/type of shares if possible Situation previous to theusing the ISIN CODE Triggering transaction (vi) Number of Number of voting shares Rights (viii) N/A N/A Resulting situation after the triggering transaction (vii) Class/type of shares Number of shares Number of voting rights % of voting rightsif possible using (ix)the ISIN CODE Direct Direct (x) Indirect (xi) Direct Indirect 0 0 1,426,000 0% 8.17% B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Date Exercise/Conversion Number of voting % of votingfinancial (xiii) Period/ Date (xiv) rights that may be rightsinstrument acquired if the instrument is exercised/ converted. N/A Total (A+B)Number of voting % of votingrights rights 1,476,000 8.17% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable (xv): Total disclosable holding for JPMorgan Chase & Co. : 1,426,000 voting rights(8.17%) Holdings by controlled undertakings of JPMorgan Chase & Co. are as follows: JPMorgan Asset Management (UK) Limited : 1,426,000 voting rights (8.17%) Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: This notification of disclosable holding as at 20 January 2007 14. Contact name: Shoaib Shaikh 15. Contact telephone number: 020 7777 0423 Annex to Notification Of Major Interests In Shares (xvi) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): JPMorgan Chase & Co Contact address (registered office for legal entities): 270 Park Avenue, New York, NY 10017 Phone number: 001 212 270 6000 Other useful information (at least legal representative for legal persons): ................. B: Identity of the notifier, if applicable (xvii) Full name: Shoaib Shaikh Contact address: JPMorgan Chase Bank. N.A. 13 Floor, 125 London Wall, London Phone number: 020 7777 0423 Other useful information (e.g. functional relationship with the person or legalentity subject to the notification obligation): ................. C: Additional information : ................. Notes to the Forms (i) This form is to be sent to the issuer or underlying issuer and to be filedwith the competent authority. (ii) Either the full name of the legal entity or another method for identifyingthe issuer or underlying issuer, provided it is reliable and accurate. (iii) This should be the full name of (a) the shareholder; (b) the personacquiring, disposing of or exercising voting rights in the cases provided for inDTR5.2.1 (b) to (h); (c) all the parties to the agreement referred to inDTR5.2.1 (a), or (d) the direct or indirect holder of financial instrumentsentitled to acquire shares already issued to which voting rights are attached,as appropriate. In relation to the transactions referred to in points DTR5.2.1 (b) to (h), thefollowing list is provided as indication of the persons who should be mentioned: - in the circumstances foreseen in DTR5.2.1 (b), the person that acquires thevoting rights and is entitled to exercise them under the agreement and thenatural person or legal entity who is transferring temporarily for considerationthe voting rights; - in the circumstances foreseen in DTR 5.2.1 (c), the person holding thecollateral, provided the person or entity controls the voting rights anddeclares its intention of exercising them, and person lodging the collateralunder these conditions; - in the circumstances foreseen in DTR5.2.1(d), the person who has a lifeinterest in shares if that person is entitled to exercise the voting rightsattached to the shares and the person who is disposing of the voting rights whenthe life interest is created; - in the circumstances foreseen in DTR5.2.1 (e), the parent undertaking and,provided it has a notification duty at an individual level under DTR 5.1, underDTR5.2.1 (a) to (d) or under a combination of any of those situations, thecontrolled undertaking; - in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of theshares, if he can exercise the voting rights attached to the shares depositedwith him at his discretion, and the depositor of the shares allowing the deposittaker to exercise the voting rights at his discretion; - in the circumstances foreseen in DTR5.2.1 (g), the person that controls thevoting rights; - in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he canexercise the voting rights at his discretion, and the shareholder who has givenhis proxy to the proxy holder allowing the latter to exercise the voting rightsat his discretion. (iv) Applicable in the cases provided for in DTR 5.2.1 (b) to (h). This shouldbe the full name of the shareholder who is the counterparty to the naturalperson or legal entity referred to in DTR5.2. (v) The date of the transaction should normally be, in the case of an onexchange transaction, the date on which the matching of orders occurs; in thecase of an off exchange transaction, date of the entering into an agreement. The date on which threshold is crossed should normally be the date on which theacquisition, disposal or possibility to exercise voting rights takes effect (seeDTR 5.1.1R (3)). For passive crossings, the date when the corporate event tookeffect. (vi) Please refer to the situation disclosed in the previous notification, Incase the situation previous to the triggering transaction was below 3%, pleasestate 'below 3%'. (vii) If the holding has fallen below the minimum threshold , the notifyingparty should not be obliged to disclose the extent of the holding, only that thenew holding is less than 3%. For the case provided for in DTR5.2.1(a), there should be no disclosure ofindividual holdings per party to the agreement unless a party individuallycrosses or reaches an Article 9 threshold. This applies upon entering into,introducing changes to or terminating an agreement. (viii) Direct and indirect (ix) In case of combined holdings of shares with voting rights attached 'directholding' and voting rights 'indirect holdings', please split the voting rightsnumber and percentage into the direct and indirect columns-if there is nocombined holdings, please leave the relevant box blank. (x) Voting rights to shares in respect of which the notifying party is a directshareholder (DTR 5.1) (xi) Voting rights held by the notifying party as an indirect shareholder (DTR5.2.1) (xii) If the holding has fallen below the minimum threshold, the notifying partyshould not be obliged to disclose the extent of the holding, only that the newholding is below 3%. (xiii) date of maturity / expiration of the finical instrument i.e. the datewhen the right to acquire shares ends. (xiv) If the financial instrument has such a period-please specify the period-for example once every three months starting from the (date) (xv) The notification should include the name(s) of the controlled undertakingsthrough which the voting rights are held. The notification should also includethe amount of voting rights and the percentage held by each controlledundertaking, insofar as individually the controlled undertaking holds 5% ormore, and insofar as the notification by the parent undertaking is intended tocover the notification obligations of the controlled undertaking. (xvi ) This annex is only to be filed with the competent authority. (xvii) Whenever another person makes the notification on behalf of theshareholder or the natural person/legal entity referred to in DTR5.2 and DTR5.3 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th May 202610:20 amRNSHolding(s) in Company
14th May 202612:26 pmRNSHolding(s) in Company
12th May 20267:00 amRNSAdaptix receives CE Certification
6th May 20264:28 pmRNSHolding(s) in Company
30th Apr 20262:42 pmRNSHolding(s) in Company
30th Apr 20262:41 pmRNSExercise of Options & TVR
24th Apr 20262:54 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSStrong Nuclear Orders for Avingtrans
26th Mar 20267:00 amRNS-RScientific Magnetics Ships 20th Quantum Magnet
4th Mar 20267:00 amRNSHolding(s) in Company
25th Feb 20267:00 amRNSInterim Results
12th Feb 202611:49 amRNSHolding(s) in Company
6th Feb 202610:24 amRNSHolding(s) in Company
27th Jan 20265:42 pmRNSExercise of Options & TVR
21st Jan 20267:00 amRNSTrading Update and Notice of Results
12th Jan 20265:13 pmRNSIssue of Share Options
12th Jan 20267:00 amRNS-RMedical & Industrial Imaging Division Appointment
8th Dec 20252:34 pmRNSNotification of Major Holdings
27th Nov 20251:59 pmRNSResult of AGM - Board Appointment
14th Nov 20258:38 amRNSExercise of Options & PDMR Dealings
10th Nov 20257:00 amRNSAdaptix receives FDA 510(K) clearance
1st Oct 20254:52 pmRNSExercise of Options & Total Voting Rights
1st Oct 20253:32 pmRNSHolding(s) in Company
29th Sep 20257:00 amRNSAppointment of Medical Division CEO
24th Sep 20257:00 amRNSPreliminary results for the year ended 31 May 2025
11th Sep 20258:00 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSHayward Tyler Secures $16m Nuclear Contracts
28th Aug 20257:00 amRNSBooth Industries secures £8.5m HS2 & TfL contracts
25th Jun 20257:00 amRNSTrading Update and Notice of Results
28th May 20257:00 amRNSTrading Update
26th Feb 20257:00 amRNSInterim Results
13th Feb 20257:00 amRNSBooth Industries secures £4.5m Contract
16th Jan 20257:00 amRNSTrading Update & Notice of Results
21st Nov 20244:09 pmRNSResult of AGM
24th Oct 20249:07 amRNSHolding(s) in Company
25th Sep 20247:00 amRNSPreliminary results for the year ended 31 May 2024
3rd Jul 20247:00 amRNSPDMR Dealings
19th Jun 20247:00 amRNSTrading Update and Notice of Results
26th Mar 202411:15 amRNSPDMR Dealings
21st Mar 20245:15 pmRNSExercise of Options, PDMR Dealings & TVR
20th Mar 20243:39 pmRNSHolding(s) in Company
4th Mar 20246:10 pmRNSPDMR Dealings
28th Feb 20247:00 amRNSInterim Results
18th Jan 20247:00 amRNSTrading Update and Notice of Results
15th Dec 20233:00 pmRNSExercise of Options & TVR
4th Dec 20237:00 amRNSMagnetica Limited appoints US distributor
22nd Nov 20237:00 amRNSEmployee & PDMR Share Incentive Awards
16th Nov 20232:20 pmRNSResult of AGM
13th Nov 20237:00 amRNSHayward Tyler Contract Win
11th Oct 20237:00 amRNSContract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.